The Importance of Diversity in Clinical Trials and the Impact of FDA Guidance

---

Diversity in clinical trials is not just a matter of fairness— it is a scientific imperative. Historically, clinical studies have underrepresented certain populations, which has led to gaps in our understanding of how different groups respond to medical treatments. A 2020 FDA report showed that 75% of participants in clinical trials for new molecular entities were white, while only 11% were Hispanic or Latino, 8% were Black or African American, and 6% were Asian. But the disparities can often go beyond race, traced to gender, age, socio-economic representation, and even sexual orientation. This lack of diversity can result in disparities in health outcomes, as treatments may not be as effective or safe for all population segments.  

The FDA Guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies is expected to be released this year and represents a significant step forward in addressing these disparities. This guidance emphasizes the necessity of incorporating Diversity Action Plans (DAPs) in the planning and execution of clinical trials. By mandating that researchers proactively include participants from diverse backgrounds, the FDA aims to ensure that clinical trial results are more generalizable and applicable to the broader public.  

Moreover, participant engagement is expected to see significant improvements. With a focus on diversity, trial designs can be more inclusive, addressing potential barriers such as language, cultural sensitivities, and logistical challenges. Engaging community leaders and leveraging local resources can also enhance participation rates and retention. As sponsors look to understand the impacts their trials have on all types of diversity, there are dual-sided benefits, in that sponsor companies are educated on the public’s perception of clinical trials, specifically from diverse participants, and the public is educated more on the actual clinical trial process. By prioritizing the inclusion of diverse populations, educational initiatives can be tailored to raise awareness and understanding about the importance of clinical trial participation among underrepresented groups. This can lead to better engagement and trust in the medical research process.  

Site identification is another critical area where the FDA’s guidance will play a pivotal role. Identifying trial sites in areas that serve underrepresented populations will be imperative to enrolling more representative trial populations. This strategic approach can enhance the study findings’ relevance and foster equity in clinical research.  

The benefits of this guidance are profound. For the scientific community, it means more robust and reliable data, leading to better-informed decisions about the efficacy and safety of treatments across diverse populations. For public health, it translates to more personalized and effective healthcare interventions, ultimately contributing to reduced health disparities and improved outcomes for all. The upcoming finalization of the FDA Guidance on Diversity Action Plans is a crucial development that promises to enhance the inclusiveness and relevance of clinical trials. By fostering diversity, we move a tiny step closer to achieving equitable healthcare and advancing public health for everyone.  

---

Related Insights:

Diversity & Inclusion

FDA’s Path Toward Diversity in Clinical Trials: The DEPICT Act and Sponsor Responsibility

Whitepapers

The DEI Mandate: What’s on the Horizon and What’s Needed for IRB and Recruitment Processes (Part 1 of 2)

Videos

The DEI Mandate: How to Accelerate Diversity Initiatives with Data Analytics and Planning (Part 2 of 2)

Videos